Chemotherapy

Patients receiving chemotherapy
#Chemotherapy #Neuropathy #Oncology

Nerve health formulation launches in US to support chemotherapy patients

Novilora has launched in the US, bringing a science-based approach to supporting nerve health for people living through and beyond cancer treatment.   Formulated by Italian internist and oncologist Dr Raffaele Migliaccio and sold in Europe as OnLife, Novilora combines palmitoylethanolamide (PEA) with a defined profile of fatty… Read More

#News

#Brain cancer #Chemotherapy #Oncology #The University of Manchester

Glioblastoma therapy timing could be key to treatment

Scientists have identified a brief window after brain tumour surgery during which a treatment for glioblastoma can cross the brain’s protective barrier and reach the cancer cells most likely to trigger tumour regrowth.  The discovery could pave the way for more effective treatments for glioblastoma, the most… Read More

#Cancer Research #Editor's Choice #News

Active nerve cells
#AnHorn Medicines #Chemotherapy #Market reporting #Neuropathy #Phase I trial

Phase I study for prevention of chemotherapy-induced peripheral neuropathy

AnHorn Medicines has dosed the first subject in the Phase I clinical trial of AH-008, a first-in-class neuroprotective candidate being developed to prevent chemotherapy-induced peripheral neuropathy (CIPN). This milestone marks the clinical advancement of a novel therapeutic approach designed to address one of the most common and debilitating complications of… Read More

#News

Biliary tract
#Biliary tract cancer #Chemotherapy #Oncology #Pusan National University #Yonsei University

Study finds new treatment option for biliary tract cancer

Researchers have found that that FOLFIRINOX, a chemotherapy used for pancreatic cancer, may improve survival in advanced biliary tract cancer (BTC) patients.  A new collaborative study from Pusan National University and Yonsei University suggests that the FOLFIRINOX regimen showed numerically improved survival outcomes compared to current standards… Read More

#Cancer Research #News

Cancer cells
#Chemotherapy #Drug discovery #Neuropathy #Oncology

Reducing the side-effects of chemotherapy  

DDW speaks to Yasuo Nakamura, Senior Executive Officer at Pharmaceuticals R&D, Asahi Kasei Pharma Corporation about the challenges of treating chemotherapy-induced peripheral neuropathy (CIPN) and the company’s current pipeline targeting the condition.   DDW: What makes chemotherapy-induced peripheral neuropathy (CIPN) such a persistent challenge in colorectal cancer care, and why has… Read More

#Exclusive Content

Cancer cells
#Chemotherapy #Genetics / genomics #Oncology #University of Cambridge #Wellcome Sanger Institute

Chemotherapy finding could guide better treatments

For the first time, scientists have systematically studied the genetic effects of chemotherapy on healthy tissues.  Researchers from the Wellcome Sanger Institute, the University of Cambridge, Cambridge University Hospitals NHS Foundation Trust (CUH) and their collaborators analysed blood cell genomes from 23 patients of all ages who… Read More

#Cancer Research #News

Patients receiving chemotherapy
#Biomarkers #Chemotherapy #Chemotherapy-resistance #Oncology #Tailor Bio

Biomarkers for chemo resistance unlock path to targeted therapies

Techbio Tailor Bio has published a pivotal study demonstrating the power of chromosomal instability (CIN) signatures to predict resistance to widely used chemotherapy drugs across multiple cancer types.  The study, carried out in collaboration with the University of Cambridge and the Spanish National Cancer… Read More

#Cancer Research #Editor's Choice #News

Scotland flag
#Chemotherapy #Hearing Loss #NHS Scotland #Norgine #Scottish Medicines Consortium (SMC)

SMC okays Pedmarqsi to prevent cisplatin-induced hearing loss

Pedmarqsi (sodium thiosulfate solution for infusion) has become the first treatment to be made available within NHS Scotland for the prevention of ototoxicity (hearing loss) induced by cisplatin chemotherapy in patients up to 18 years of age with localised, non-metastatic, solid tumours.  The decision follows that of the National Institute… Read More

#News #Regulatory

Stomach pain
#Cancer treatment #Chemotherapy #Napo Pharmaceuticals #Oncology #Preclinical investigations #Puma Biotechnology

Prescription drug could prevent cancer therapy-related diarrhoea

A study in dogs has shown that crofelemer can provide symptomatic relief of diarrhoea associated with the irreversible pan-human epidermal growth factor receptor (HER) tyrosine kinase inhibitor (TKI) neratinib (Nerlynx). Puma Biotechnology’s Nerlynx is a pan HER TKI indicated for the extended adjuvant treatment of adult… Read More

#Cancer Research #News

Stamp of approval
#Chemotherapy #European Commission #Leukaemia #Oncology #Otsuka

European Commission approves oral treatment for leukaemia

The European Commission (EC) has approved INAQOVI (oral decitabine and cedazuridine) as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy. INAQOVI, developed by Otsuka Pharmaceutical and Astex Pharmaceuticals, is the first oral hypomethylating agent to be licensed… Read More

#News #Regulatory

European Commission
#Chemotherapy #European Commission #Jazz Pharmaceuticals #Leukaemia #Paediatrics

EC approves Erwinia-derived asparaginase for leukaemia

The European Commission (EC) has granted marketing authorisation for Jazz Pharmaceuticals’ Enrylaze as part of a multi-agent regimen for acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL). The treatment is approved in adult and paediatric patients who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase. Enrylaze, approved as Rylaze… Read More

#News #Regulatory

Patients receiving chemotherapy
#Adverse event #Cancer treatment #Chemotherapy #MHRA #NHS #Unlicensed drug

Patient dies after receiving unlicensed drug

A cancer patient died and three others were hospitalised in the UK after they were administered an unlicensed version of chemotherapy cabazitaxel. According to The Guardian, which reported on the incident, the problem was caused by an issue at private healthcare company Sciensus’… Read More

#News #Trending News

Cancer cell
#Cancer research #Chemotherapy #Drug development #National Institute for Health and Care Excellence (NICE) #Regulatory

Positive NICE recommendation for BRCAm ovarian cancer 

AstraZeneca UK announced that Lynparza (olaparib) is recommended by the National Institute for Health and Care Excellence (NICE) for maintenance treatment of BRCA-mutated relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults who have had two or more courses of platinum-based chemotherapy.  BRCA1 and BRCA2 are… Read More

#Editor's Choice #News #Regulatory #Trending News

Clinical trial
#Biotechnology #Chemotherapy #Clinical trials #Immunotherapy

Data shows significant results in cancer-associated fibrosis models 

Redx, a clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of cancer and fibrotic disease, announced preclinical data for its lead fibrosis asset, RXC007, and the Discodin Domain Receptor (DDR)1/2 discovery programme.   The data were from preclinical models of… Read More

#News

#Chemotherapy #EpicentRx #FDA #Head and neck cancer #Oncology #Phase II trial

US FDA fast-tracks drug to prevent severe chemotherapy side effect

The US Food and Drug Administration (FDA) has granted Fast Track Designation to RRx-001 for the prevention/attenuation of severe oral mucositis in chemotherapy and radiation-treated head and neck cancer patients. The FDA also accepted the company's Investigational New Drug (IND) application to initiate a follow-on Phase IIb clinical trial, called… Read More

#News #Regulatory

Stamp of approval
#AstraZeneca #Cancer #Chemotherapy #Clinical research #MHRA #Oncology

First-line AZ treatment for adults with biliary tract cancer approved 

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to AstraZeneca for Imfinzi (durvalumab) in combination with gemcitabine and cisplatin in Great Britain for use as a first-line treatment of adults with locally advanced, unresectable or metastatic biliary tract cancer (BTC).1 This authorisation by… Read More

#Cancer Research #News